Top 10 Peptide Synthesis Companies
.png)
Published: May 2024
The future success of the peptide synthesis market is driven by strategic initiaives by peptide API contract manufacturers. We analyzed over 75 companies that are engaged in the contract manufacturing of peptide APIs. In this article, discover top 10 peptide synthesis companies and their service portfolio related to peptide synthesis.
Peptides are the signaling molecules that bind to specific receptors present on the cell surface and trigger intracellular effects. These molecules are capable of regulating the physiological functions and metabolic synthesis of various components, as well as providing nutrition to the body. It is worth noting that peptides are polymers of amino acids, which are linked through peptide bonds formed between the carboxyl group and the amine group. When these peptides are linked together, they form a polypeptide; molecules containing two to ten amino acids are known as oligopeptides, while those having more than ten amino acids are called polypeptides. Further, subsequent linking of polypeptides leads to the formation of proteins.
Peptide therapeutics have become a prominent segment in the overall biopharmaceutical domain. It is worth highlighting that over 80 peptide therapeutics have been approved till date, across the globe, while more than 300 molecules are being evaluated in clinical trials across different phases of development. The increasing popularity and demand for peptide drugs can be attributed to the fact that these therapeutic candidates have demonstrated capability to treat a myriad of disorders, including various cardiovascular disorders, metabolic disorders and oncological disorders. Driven by such high demand, specifically for GLP-1 drugs, and technological advancements, the peptide synthesis market is poised to grow in the long-run.
Roots Analysis has conducted an exhaustive study on peptide synthesis market featuring the current market landscape and future opportunity for the companies offering contract manufacturing services for peptide synthesis, over a span of 12 years.
Table of Contents
Below, we have listed (in alphabetical order), the top 10 peptide synthesis companies.
- AmbioPharm
- Auspep
- Bachem
- BCN Peptides
- Chinese Peptide
- CordenPharma
- CPC Scientific
- CSBio
- Peptide Institute
- PolyPeptide
Interested in exploring all 75+ peptide synthesis companies, including GLP manufacturing, and their recent initiatives?
Discover Below the Details on 5 of the top 10 Peptide Synthesis Companies
Let us deep dive to understand the activity of the 5 of the top 10 peptide synthesis companies (shortlisted on the basis of service portfolio). It is essential to note that the selection of top players can differ substantially according to the defined criteria.
AmbioPharm is Setting New Benchmarks in Comprehensive cGMP Peptide Manufacturing
1. AmbioPharm
AmbioPharm is a US-based company that claims to offer cGMP manufacturing services for peptide APIs, across all scales of operation. Additionally, it is engaged in the production of generic peptide-based products at commercial scale and provides non-GMP manufacturing services for peptides for clinical research purposes. It is also worth highlighting that the company uses various chemical methods, such as solid phase synthesis, solution phase and hybrid phase synthesis to carry out manufacturing operations.
AmbioPharm: Company Details
| Particulars | Specifications |
| Company Logo |  |
| Year of Establisment | 2005 |
| Number of Employees | 501-1,000 |
| Headquarter |  |
| Key Executives |
|
AmbioPharm: Overview of Peptide Manufacturing Capabilities
| S.No. | Key Parameters | US-based Facility | China-based Facility |
| 1 | Number of Manufacturing Facilities | 1 | 1 |
| 2 | Location | South Carolina | Shanghai |
| 3 | GMP Compliant | Yes | Yes |
| 4 | Scale of Operation | Preclinical, clinical and commercial | Preclinical, clinical and commercial |
| 5 | Area Dedicated for Peptide Manufacturing | 82,566 sq. ft. | 380,550 sq. ft. |
| 6 | Peptide Synthesis Method Used | Solid phase and solution phase synthesis | Solid phase and solution phase synthesis |
| 7 | Purification Technique Used | HPLC | HPLC |
| 8 | Number of Employees | >200 | >375 |
| 9 | Accreditations | USFDA | USFDA |
Recent Development: In September 2023, AmbioPharm entered into a partnership with CombiGene to develop COZY01 peptide for Zynero and Combigene’s combined peptide-based pain project.
Further details on recent initiatives taken by AmbioPharm as well as other peptide synthesis companies have been provided in detail in the report.
Auspep is Australian Peptide Manufacturer with GMP Certification, Offering Custom Peptide Synthesis and Peptide Modification Services
2. Auspep
Auspep is an Australian company that claims to be engaged in the manufacturing of peptide APIs, at small and large scale of operation. In addition, it provides peptide modification services, such as the incorporation of unnatural amino acids, complex and custom peptides, using a range of innovative technologies. Furthermore, the company claims to be the peptide manufacturer in Australia to have received GMP certification.
Auspep: Company Details
| Particulars | Specifications |
| Company Logo |  |
| Year of Establisment | 1987 |
| Number of Employees | 11-50 |
| Headquarter |  |
| Key Executives |
|
Auspep: Overview of Peptide Manufacturing Capabilities
| S.No. | Key Parameters | Australia-based Facility |
| 1 | Number of Manufacturing Facilities | 1 |
| 2 | Location | Melbourne |
| 3 | GMP Compliant | Yes |
| 4 | Scale of Operation | Preclinical, clinical and commercial |
| 5 | Peptide Synthesis Methos Used | Solid phase and Liquid phase synthesis |
| 6 | Purification Technique Used | HPLC |
| 7 | Accreditations | USFDA and EMA |
Recent Development: In February 2023, Auspep entered into a partnership with Argenica Therapeutics for a preclinical program that is designed to assess the efficacy of ARG-007 for the treatment of mild to moderate traumatic brain injury.
Further details on recent initiatives taken by Auspep as well as other peptide synthesis companies have been provided in detail in the report.
Bachem is Amongst the Leading Peptide Synthesis Companies with Innovative Molecular Hiving Technology
3. Bachem
Bachem, a Switzerland-based company with an experience of 50 years in this domain, claims to be engaged in the development of a wide range of peptides. Additionally, the firm states to provide customized peptides to cater to the needs of researchers based across the globe. As per the firm’s website, it is engaged in the manufacturing of cosmetic peptides using the Molecular Hiving technology, licensed from JITSUBO.
Bachem: Company Details
| Particulars | Specifications |
| Company Logo |  |
| Year of Establisment | 1971 |
| Number of Employees | 1,001-5,000 |
| Headquarter |  |
| Key Executives |
|
Bachem: Overview of Peptide Manufacturing Capabilities
| S.No. | Key Parameters | US-based Facility | Switzerlan-based Facility |
| 1 | Number of Manufacturing Facilities | 2 | 2 |
| 2 | Location | Carolina | Bubendrof and Vionnaz |
| 3 | GMP Compliant | Yes | Yes |
| 4 | Scale of Operation | Preclinical, clinical and commercial | Preclinical, clinical and commercial |
| 5 | Peptide Synthesis Method Used | Solid and solution phase synthesis | Solid and solution phase synthesis |
| 6 | Purification Technique Used | HPLC, ion-exchange and size-exclusion chromatography |
HPLC, ion-exchange and size-exclusion chromatography |
| 7 | Manufacturing Capacity | Solution phase: 8,000 L Solid phase: 150 L |
Solution phase: 8,000 L Solid phase: 150 L |
| 8 | Accreditations | USFDA | USFDA and Swissmedic |
Recent Development: In March 2023, Bachem entered into a long-term partnership with an undisclosed partner for providing large volumes of peptides, which is expected to be worth nearly CHF 500 million, for the period 2027- 2031. Further, in the same month, company raised CHF 108.1 million through secondary offering, which the company plans to utilize for capacity expansion of its numerous production facilities.
Further details on recent initiatives taken by Bachem as well as other peptide synthesis companies have been provided in detail in the report.
CordenPharma Expands Early Clinical Peptide Manufacturing to Launch IND-Targeted Peptide API to Injectable Drug Product
4. CordenPharma
CordenPharma is a German CDMO that claims to be engaged in providing a wide range of services for APIs, drug products and pharma packaging. As per the firm’s website, it currently supports the development of more than 50 cGMP projects, involving both New Chemical Entities (NCEs) as well as peptide generics. Additionally, it states to have various proprietary technology platforms for the development of peptides, lipids and carbohydrates, injectables, small molecules and antibiotics. It is worth highlighting that in May 2022, CordenPharma was acquired by Astorg.
CordenPharma: Company Details
| Particulars | Specifications |
| Company Logo |  |
| Year of Establisment | 2006 |
| Number of Employees | 1,001-5,000 |
| Headquarter |  |
| Key Executives |
|
CordenPharma: Overview of Peptide Manufacturing Capabilities
| S.No. | Key Parameters | US-based Facility | Belgium-based Facility | Germany-based Facility |
| 1 | Number of Manufacturing Facilities | 1 | 1 | 1 |
| 2 | Location | Colorado | Brussels | Frankfurt |
| 3 | GMP Compliant | Yes | Yes | Yes |
| 4 | Scale of Operation | Commercial | Preclinical, clinical and commercial | Preclinical, clinical and commercial |
| 5 | Peptide Synthesis Method Used | Liquid phase synthesis | Liquid phase, solid phase and hybrid synthesis | Liquid phase and solid phase |
| 6 | Purification Technique Used | Ion-exchange, size-exclusion chromatography | HPLC, UPLC and ion-exchange chromatography | HPLC |
| 7 | Manufacturing Capacity | 10,000 L | Large scale-up to 100 kg Medium scale-up to 10 kg Small scale-up to 2 kg |
Milligrams to multi 100 grams |
| 8 | Accreditations | USFDA | USFDA and EMA | - |
Recent Development: In April 2024, CordenPharma announed the commissioning of new 1,000 m2 GMP capacities at Frankfurt to manufacture early clinical phase peptide APIs.
Further details on recent initiatives taken by CordenPharma as well as other peptide synthesis companies have been provided in detail in the report.
Peptide Institute is Pioneering Peptide Manufacturing by Offering Comprehensive Services from Research and Development to Commercialization
5. Peptide Institute
Peptide Institute was formed as a spin off from the Osaka University Institute for Protein Research Foundation, in 1977. The company claims to provide a wide range of services for peptide drug substances, spanning from research and development to commercialization.
Peptide Institute: Company Details
| Particulars | Specifications |
| Company Logo |  |
| Year of Establisment | 1977 |
| Headquarter |  |
| Key Executives |
|
Peptide Institute: Overview of Peptide Manufacturing Capabilities
| S.No. | Key Parameters | Japan-based Facility |
| 1 | Number of Manufacturing Facilities | 1 |
| 2 | Location | Osaka |
| 3 | GMP Compliant | Yes |
| 4 | Scale of Operation | Preclinical, clinical and commercial |
| 5 | Peptide Synthesis Methos Used | Solid phase and solution phase synthesis |
| 6 | Purification Technique Used | HPLC and ion-exchange chromatography |
| 7 | Manufacturing Capacity | 10 mg to Kg |
| 8 | Accreditations | ICH |
Recent Development: In order to help support the development of therapeutics and vaccines against the novel coronavirus (COVID-19), the company entered into a product development agreement with AnGes in April 2020.
Further details on recent initiatives taken by Peptide Institute as well as other peptide synthesis companies have been provided in detail in the report.
What About the Peptide Synthesis Companies Around the World?
The above presentation features details on 5 of the top 10 peptide synthesis companies selected from a pool of more than 75 companies that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
Sources
- https://www.perroninstitute.org/argenica-awarded-1-2m-grant-for-traumatic-brain-injury-project/
- https://www.bachem.com/news/bachem-signs-long-term-cooperation-agreement-for-the-development-and-supply-of-peptides/
- https://www.bcnpeptides.com/successful-regulatory-inspections-and-gmp-renewal/
- https://cordenpharma.com/articles/integrated-peptide-injectable-manufacturing-targeted-for-first-in-human-clinical-trials/
- https://cpcscientific.com/cpc-scientific-announces-new-california-peptide-manufacturing-facility/
- https://www.csbio.com/blog/nervgen.html
- https://pj.jiho.jp/article/241915
- https://www.polypeptide.com/news/polypeptide-signs-scientific-collaboration-agreement/